Dopaminergic Neuron Loss in Mice Due to Increased Levels of Wild-type Human α-Synuclein Only Takes Place Under Conditions of Accelerated Aging

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jan 30

PMID 38291230

Authors

Ana Perez-Villalba

Maria Salome Sirerol-Piquer

Raul Soriano-Canton

Virginia Folgado

Azucena Perez-Canamas

Martina Kirstein

Isabel Farinas

Francisco Perez-Sanchez

Affiliations

Soon will be listed here.

Abstract

Understanding the intricate pathogenic mechanisms behind Parkinson's disease (PD) and its multifactorial nature presents a significant challenge in disease modeling. To address this, we explore genetic models that better capture the disease's complexity. Given that aging is the primary risk factor for PD, this study investigates the impact of aging in conjunction with overexpression of wild-type human α-synuclein (α-Syn) in the dopaminergic system. This is achieved by introducing a novel transgenic mouse strain overexpressing α-Syn under the TH-promoter within the senescence-accelerated SAMP8 (P8) genetic background. Behavioral assessments, conducted at both 10 and 16 months of age, unveil motor impairments exclusive to P8 α-SynTg mice, a phenomenon conspicuously absent in α-SynTg mice. These findings suggest a synergistic interplay between heightened α-Syn levels and the aging process, resulting in motor deficits. These motor disturbances correlate with reduced dopamine (DA) levels, increased DA turnover, synaptic terminal loss, and notably, the depletion of dopaminergic neurons in the substantia nigra and noradrenergic neurons in the locus coeruleus. Furthermore, P8 α-SynTg mice exhibit alterations in gut transit time, mirroring early PD symptoms. In summary, P8 α-SynTg mice effectively replicate parkinsonian phenotypes by combining α-Syn transgene expression with accelerated aging. This model offers valuable insights into the understanding of PD and serves as a valuable platform for further research.

References

Lalonde R, Strazielle C . Brain regions and genes affecting limb-clasping responses. Brain Res Rev. 2011; 67(1-2):252-9. DOI: 10.1016/j.brainresrev.2011.02.005. View

Giasson B, Duda J, Quinn S, Zhang B, Trojanowski J, Lee V . Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002; 34(4):521-33. DOI: 10.1016/s0896-6273(02)00682-7. View

Giguere N, Burke Nanni S, Trudeau L . On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease. Front Neurol. 2018; 9:455. PMC: 6018545. DOI: 10.3389/fneur.2018.00455. View

Takeda T . Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem Res. 2009; 34(4):639-59. DOI: 10.1007/s11064-009-9922-y. View

Yuan Z, Gu P, Liu L, Wang Y, Liu J, Cui D . Neuroprotective effects of enriched environment in MPTP-treated SAMP8 mice. Neurosci Lett. 2009; 454(1):6-10. DOI: 10.1016/j.neulet.2009.02.058. View

Kuo Y, Li Z, Jiao Y, Gaborit N, Pani A, Orrison B . Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet. 2010; 19(9):1633-50. PMC: 2850613. DOI: 10.1093/hmg/ddq038. View

Akiguchi I, Pallas M, Budka H, Akiyama H, Ueno M, Han J . SAMP8 mice as a neuropathological model of accelerated brain aging and dementia: Toshio Takeda's legacy and future directions. Neuropathology. 2017; 37(4):293-305. DOI: 10.1111/neup.12373. View

Zarow C, Lyness S, Mortimer J, Chui H . Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003; 60(3):337-41. DOI: 10.1001/archneur.60.3.337. View

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

10.

Martin G, Austad S, Johnson T . Genetic analysis of ageing: role of oxidative damage and environmental stresses. Nat Genet. 1996; 13(1):25-34. DOI: 10.1038/ng0596-25. View

11.

Lee M, Stirling W, Xu Y, Xu X, Qui D, Mandir A . Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 2002; 99(13):8968-73. PMC: 124407. DOI: 10.1073/pnas.132197599. View

12.

Janezic S, Threlfell S, Dodson P, Dowie M, Taylor T, Potgieter D . Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci U S A. 2013; 110(42):E4016-25. PMC: 3801069. DOI: 10.1073/pnas.1309143110. View

13.

Bourdenx M, Dovero S, Engeln M, Bido S, Bastide M, Dutheil N . Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression. Acta Neuropathol Commun. 2015; 3:46. PMC: 4513748. DOI: 10.1186/s40478-015-0222-2. View

14.

Baloyannis S, Costa V, Baloyannis I . Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease. J Neurol Sci. 2006; 248(1-2):35-41. DOI: 10.1016/j.jns.2006.05.006. View

15.

Perfeito R, Lazaro D, Outeiro T, Rego A . Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells. Mol Cell Neurosci. 2014; 62:51-9. DOI: 10.1016/j.mcn.2014.08.002. View

16.

Karasawa N, Nagatsu I, Sakai K, Nagatsu T, Watanabe K, Onozuka M . Immunocytochemical study of catecholaminergic neurons in the senescence-accelerated mouse (SAM-P8) brain. J Neural Transm (Vienna). 1997; 104(11-12):1267-75. DOI: 10.1007/BF01294727. View

17.

Hosokawa M . A higher oxidative status accelerates senescence and aggravates age-dependent disorders in SAMP strains of mice. Mech Ageing Dev. 2002; 123(12):1553-61. DOI: 10.1016/s0047-6374(02)00091-x. View

18.

Guyenet S, Furrer S, Damian V, Baughan T, La Spada A, Garden G . A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp. 2010; (39). PMC: 3121238. DOI: 10.3791/1787. View

19.

Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J . alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302(5646):841. DOI: 10.1126/science.1090278. View

20.

Volpicelli-Daley L, Kirik D, Stoyka L, Standaert D, Harms A . How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?. J Neurochem. 2016; 139 Suppl 1:131-155. PMC: 5040622. DOI: 10.1111/jnc.13627. View